Perceptive Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Perceptive Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-489	Closed	-$252K	–	144
2020 Q3	$252K	Sell	489 -15,000	-97%	-$7.6M	﹤0.01%	125
2020 Q2	$6.99M	Buy	15,489 +12,000	+344%	+$5.3M	0.11%	88
2020 Q1	$1.22M	Sell	3,489 -65,000	-95%	-$23.9M	0.03%	92
2019 Q4	$25.3M	Buy	68,489 +3,489	+5%	+$1.23M	0.5%	44
2019 Q3	$21.6M	Buy	+65,000	New	+$21.2M	0.58%	43
2017 Q2	–	Sell	-49,416	Closed	-$9.85M	–	137
2017 Q1	$9.85M	Buy	49,416 +25,000	+102%	+$4.82M	0.56%	43
2016 Q4	$4.45M	Buy	24,416 +14,416	+144%	+$2.46M	0.32%	60
2016 Q3	$1.64M	Buy	+10,000	New	+$1.52M	0.11%	92

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Perceptive Advisors's BIO Position: Q4 2020 in Review

Perceptive Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2020, closing a stake of 489 shares — an estimated $252K sold.

Perceptive Advisors first reported a position in BIO in Q3 2016 and held it in 8 quarters. The position peaked at $25.3M in Q4 2019. 491 funds tracked by Wall St. Rank hold BIO as of Q4 2020.

Perceptive Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q4 2020 after selling out during the quarter.
Perceptive Advisors sold 489 Bio-Rad Laboratories Class A shares in Q4 2020, an estimated $252K.
Perceptive Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2016 and held it in 8 quarters.
Perceptive Advisors's Bio-Rad Laboratories Class A position peaked at $25.3M in Q4 2019.
491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2020.

Based on Perceptive Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.